Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MPI | P34949 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26577911 | 0.86 | NQO2 (0.53) | NQO2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL20970361 | 0.82 | NQO2 (0.48) | NQO2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL22071465 | 0.82 | NQO2 (0.48) | NQO2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL20970414 | 0.81 | NQO2 (0.38) | NQO2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL19695808 | 0.80 | NQO2 (0.47) | NQO2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL11402389 | 0.79 | NQO2 (0.46) | NQO2ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL11955002 | 0.78 | ALDH1A1 (0.48) | NQO2ALDH1A1ALOX15HSD17B10NR1I2 | |
| SCHEMBL24712674 | 0.78 | CYP1A2 (0.57) | ALDH1A1KDM4EHPGDHSD17B10CYP2C9 | |
| SCHEMBL15853141 | 0.78 | CYP1A2 (0.41) | NQO2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL26579482 | 0.78 | CYP1A2 (0.39) | ALDH1A1MEN1KMT2AHSD17B10NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-5723694-A | REACTION OF FORMALDEHYDE WITH PHENOL AND CATALYTIC HYDROGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | NQO2 446/4885ALDH1A1 3979/4885KDM4E 2546/4885 |
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NQO2 461/4885ALDH1A1 3563/4885KDM4E 2597/4885 |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | NQO2 1205/4885ALDH1A1 3457/4885KDM4E 3508/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NQO2 114/4885ALDH1A1 3753/4885KDM4E 3345/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | NQO2 1318/4885ALDH1A1 4178/4885KDM4E 3220/4885 |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | NQO2 1933/4885ALDH1A1 4243/4885KDM4E 3751/4885 |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | NQO2 1933/4885ALDH1A1 4243/4885KDM4E 3751/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NQO2 1209/4885ALDH1A1 3193/4885KDM4E 3093/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | NQO2 48/4885ALDH1A1 3174/4885KDM4E 4039/4885 |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NQO2 147/4885ALDH1A1 2059/4885KDM4E 3157/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | NQO2 1821/4885ALDH1A1 1577/4885KDM4E 4202/4885 |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NQO2 138/4885ALDH1A1 3333/4885KDM4E 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.